ACURX PHARMACEUTICALS INC (ACXP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.140.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ACURX PHARMACEUTICALS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.363
Annual ending 2026-12-31
Revenue	—	276,000
EPS	—	-1.72
Annual ending 2027-12-31
Revenue	—	3.54M
EPS	—	-1.5

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Effective capital raise via unregistered equity sales	The company raised capital through unregistered equity sales in April 2026.	Intact	failure to raise capital or dilution worsens	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce EPS losses from current levels	Analysts expect EPS losses to improve from -$2.39 in 2026 to -$2.13 in 2027.	Intact	EPS loss worsens beyond -$2.13 in FY27	Diluted EPS: $-0.53 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -$1.5 per share. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-0.53 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7650852e-21e9-4e6f-a072-1b7edeb65b09. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Expand ibezapolstat program into recurrent C. difficile infection	Acurx aims to expand its ibezapolstat program into recurrent C.	Improving	progress score falls below 40%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain leadership salary reductions	A supporting condition in ACURX PHARMACEUTICALS INC's published investment case. The stated target is salary reductions sustained.	Intact	salary reductions reversed	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 2
2026-07-25	Unavailable	Unavailable	1 / 2
2026-07-26	Unavailable	Unavailable	1 / 2
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	1 / 2
2026-07-30	Unavailable	Unavailable	1 / 2
2026-07-31	Unavailable	Unavailable	2 / 2
2026-08-01	Unavailable	Unavailable	2 / 2
2026-08-02	Unavailable	Unavailable	2 / 2
2026-08-03	Unavailable	Unavailable	2 / 2
2026-08-04	Unavailable	Unavailable	2 / 2
2026-08-05	Unavailable	Unavailable	1 / 2
2026-08-06	Unavailable	Unavailable	2 / 2
2026-08-07	Unavailable	Unavailable	2 / 2
2026-08-08	Unavailable	Unavailable	2 / 2
2026-08-09	Unavailable	Unavailable	2 / 2
2026-08-10	Unavailable	Unavailable	2 / 2
2026-08-11	Unavailable	Unavailable	2 / 2
2026-08-12	Unavailable	Unavailable	2 / 2
2026-08-13	Unavailable	Unavailable	1 / 2
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 2
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 3
2026-08-21	Unavailable	Unavailable	1 / 3
2026-08-22	Unavailable	Unavailable	1 / 3
2026-08-23	Unavailable	Unavailable	1 / 3
2026-08-24	Unavailable	Unavailable	1 / 3
2026-08-25	Unavailable	Unavailable	1 / 3
2026-08-26	Unavailable	Unavailable	1 / 3
2026-08-27	Unavailable	Unavailable	1 / 3
2026-08-28	Unavailable	Unavailable	1 / 3
2026-08-29	Unavailable	Unavailable	1 / 3
2026-08-30	Unavailable	Unavailable	1 / 3
2026-08-31	Unavailable	Unavailable	1 / 3
2026-09-01	Unavailable	Unavailable	1 / 3
2026-09-02	Unavailable	Unavailable	1 / 3
2026-09-03	Unavailable	Unavailable	1 / 3
2026-09-04	Unavailable	Unavailable	1 / 3
2026-09-05	Unavailable	Unavailable	1 / 3
2026-09-06	Unavailable	Unavailable	1 / 3
2026-09-07	Unavailable	Unavailable	1 / 3
2026-09-08	Unavailable	Unavailable	1 / 3
2026-09-09	Unavailable	Unavailable	1 / 3
2026-09-10	Unavailable	Unavailable	1 / 3
2026-09-11	Unavailable	Unavailable	1 / 3
2026-09-12	Unavailable	Unavailable	1 / 3
2026-09-13	Unavailable	Unavailable	1 / 3
2026-09-14	Unavailable	Unavailable	1 / 3
2026-09-15	Unavailable	Unavailable	1 / 3
2026-09-16	Unavailable	Unavailable	1 / 3
2026-09-17	Unavailable	Unavailable	1 / 3
2026-09-18	Unavailable	Unavailable	1 / 3
2026-09-19	Unavailable	Unavailable	1 / 3
2026-09-20	Unavailable	Unavailable	1 / 3
2026-09-21	Unavailable	Unavailable	1 / 3
2026-09-22	Unavailable	Unavailable	1 / 3
2026-09-23	Unavailable	Unavailable	1 / 3
2026-09-24	Unavailable	Unavailable	1 / 3
2026-09-25	Unavailable	Unavailable	1 / 3
2026-09-26	Unavailable	Unavailable	1 / 3
2026-09-27	Unavailable	Unavailable	1 / 3
2026-09-28	Unavailable	Unavailable	1 / 3
2026-09-29	Unavailable	Unavailable	1 / 3
2026-09-30	Unavailable	Unavailable	1 / 3
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	1 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Effective capital raise via unregistered equity salesDirect metric needs a verified mapping
Reduce EPS losses from current levelsDiluted EPS: $-0.53 per share
Expand ibezapolstat program into recurrent C. difficile infectionDirect metric needs a verified mapping
Maintain leadership salary reductionsDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-83.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ACURX PHARMACEUTICALS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making biotech case, not an established compounder. The thesis is on watch: recent performance trails its industry cohort, while the evidence snapshot gives low confidence and mixed marks for key management priorities.

What's priced into ACURX PHARMACEUTICALS INC

The snapshot provides no valuation multiple or direct measure of market expectations, so whether ACXP looks cheap, fair, or expensive versus peers is unclear. It does show weak financial performance and a loss-making profile, but does not establish how much of those conditions the market already assumes.

What the fundamentals likely do

Near term, fundamentals face elevated earnings risk, with a 64% estimated miss probability, and recent financial performance is weak. Management’s ibezapolstat program expansion and leadership compensation alignment are both rated mixed; an April private placement and a separate negative capital-allocation event add uncertainty. Over the multi-year view, the snapshot gives too little evidence to establish a reliable path to improved results.

What ACURX PHARMACEUTICALS INC hinges on

The multi-year thesis hinges in part on whether ACXP can make progress with its ibezapolstat program while addressing mixed management and capital-allocation signals. Near term, a weakening jobs trend could add pressure to cyclical names, while continued earnings strength from VRTX, REGN, and MRNA could support the Healthcare sector backdrop; misses or lower guidance from those companies could weaken that tailwind.